[Nouveaux traitements du myélome multiple].

NEW THERAPIES IN MULTIPLE MYELOMA Multiple myeloma is the second most common hemopathy in Western countries. The development of the therapeutic arsenal has significantly improved patients' prognosis. In the early 2000s, autograft, the addition of immunomodulatory drugs and proteasome inhibitors have undoubtedly changed the face of the disease. In the last decade, a new chapter has opened, targeted therapies led by anti-CD38 and more recently the introduction of CAR T-cells and bispecific antibodies. Because of the survival improvement, quality of life is now a major concern as well as personalized treatment (adapted to cytogenetic risk or treatment response [minimal residual disease]) to overcome prognosis heterogeneity.